Abstract library

971 results for "somatostatin type 2 receptor".
#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Apostolos V. Tsolakis
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt
#819 Immunohistochemical and Genomic Evidence for the Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance, as they represent potential targets for diagnosis and treatment.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: George A Kanakis
#1581 Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms
Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Lingaku Lee
Authors: Lee L, Ito T, Kawabe K, Otsuka T, ...
#1641 Somatostatin Receptor Expression in Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is an uncommon neoplasm with an estimated annual incidence of 0.5-2 cases per million population. Surgery of the adrenal tumor is the major treatment. When complete tumor removal is not possible, or in case of recurrence, medical treatment with O,p’DDD(mitotane) is recommended. The treatment of ACC is currently based on the mitotane partial responses have been described in 19-34% of cases, and there are single reports of complete responses.The discovery of somatostatin (SST) and the identification of stable SST analogs with a longer half-life have raised new hopes for the treatment of endocrine tumors.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Iya A Voronkova
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#120 Somatostatin receptors 1-5 expression in a large series of well-differentiated neuroendocrine tumors
Introduction: For their antisecretive and antiproliferative effect somatostatin analogs (SA) have been used in the treatment of neuroendocrine tumors (NETs), based on the expression of somatostatin receptors (sstRs). The potential availability of new SA for the treatment of patients with NETs suggests a better characterization of sstRs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Paola Loli
#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis
Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Angel Diaz Perez